Roche makes another China deal Read in browser

Thank you for reading, Test Researcher! basic Subscription UPGRADE

M T W Thu F 8 October, 2026

Biopharma's balance of power is shifting, and in January, Endpoints journalists will press the people at the center of it on who's rising, who's falling and where the industry may land by the end of the decade. Join us at #JPM27 for exclusive conversations and interviews you won't get anywhere else. Save $200 on your all-access pass with Early Bird, or join us virtually for free.

presented by The Patent Clock Is Al­ready Run­ning. Why De­vel­op­ment Speed Is Al­so a Com­mer­cial Strat­e­gy

news Argenx's study flop in Sjögren's overshadows a win in celiac disease Roche does fourth China deal since August, teaming with Defand on degraders Zuckerberg's Biohub expands virtual cell effort to $1.8B, looping in Isomorphic, Meta, Google

Oct 08 11:00 am ET Site-central discordance in oncology trial imaging: New benchmarks and management strategies sponsored by Perceptive Imaging Oct 13 11:00 am ET Commercial excellence and AI - a ripple, wave or a tsunami sponsored by ZS Oct 15 1:00 pm ET Insights into Polycystic Kidney Disease: The Potential of Clinicogenomic Data sponsored by Natera Oct 20 11:00 am ET Intelligent oversight and orchestration: How mission control is redefining R&D decision-making sponsored by ZS Oct 21 11:00 am ET From prediction to decision: Digital twins and predictive modeling in clinical development sponsored by Flatiron Oct 22 11:00 am ET A new model for clinical research – Expanding community trial access sponsored by Parexel Oct 28 10:30 am ET The evolution of MRD: From molecular detection to clinical decisions sponsored by ABBOTT

The entire healthcare ecosystem is more Silicon Valley-ified than ever before. What tech has actually changed? Is biopharma behind? Find out, join us for Health Tech day.

ENDPOINTS PHARMA PhRMA sues Trump administration over GLOBE drug pricing demo program Dutch court blocks subcutaneous Keytruda in eight European countries Ultragenyx sells PRV for $210M and still has another voucher it plans to monetize WHO advises against obesity drugs for younger children

in case you missed it 1. TCGX doubles down on China with $600M Asia-focused fund 2. Vaccine for deadly brain cancer narrowly misses goal in key trial 3. Bexorg gets $28M ARPA-H award to run longer tests on ‘rebooted’ human brains